Quest Diagnostics (NYSE:DGX) SVP Sells $196,227.14 in Stock
Patrick Plewman, an SVP at Quest Diagnostics (NYSE:DGX), sold 958 shares of the company's stock for $196,227.14, reducing his stake by 5.7%. This transaction follows a previous sale of 5,662 shares for $1.16 million earlier in the month. The news comes after Quest Diagnostics reported stronger-than-expected quarterly earnings and revenue, approved a $1.0 billion share buyback, and increased its quarterly dividend.
Insider Selling: Quest Diagnostics (NYSE:DGX) SVP Sells 1,111 Shares of Stock
Quest Diagnostics (NYSE:DGX) Senior Vice President Michael Prevoznik sold 1,111 shares of the company's stock on February 19th for a total of $227,566.13, reducing his holdings by 2.81%. This transaction follows Quest Diagnostics reporting strong Q4 earnings, beating estimates, raising its dividend, and authorizing a $1.0 billion share buyback program. The company also provided positive FY2026 guidance, as institutional investors have adjusted their positions and analysts maintain a "Moderate Buy" consensus rating with an average price target of $210.29.
Quest Diagnostics (NYSE:DGX) EVP Sells $293,521.39 in Stock
Quest Diagnostics EVP Catherine Doherty sold 1,433 shares of the company's stock for $293,521.39, reducing her stake by 2.05%. This transaction followed the company's strong quarterly earnings, where it beat analyst estimates, provided optimistic FY2026 guidance, increased its dividend, and authorized a $1.00 billion share repurchase plan. DGX stock traded down slightly after the news, with a market capitalization of $22.50 billion.
DigiPower X Announces Closing of Settlement
DigiPower X Inc. announced the closing of its previously announced settlement, which received final approval from the TSX Venture Exchange on February 17, 2026. In connection with the settlement, the company issued a warrant for 269,231 subordinate voting shares at US$2.85 per share. Additionally, DigiPower X granted 200,000 stock options to certain directors, exercisable at US$2.60 and US$6.00 per share, with an expiry of January 30, 2031.
A diagnostics company moved out. Its former landlord claims it left a mess.
A diagnostics company has been sued by its former landlord in South San Francisco, who alleges that the company left the premises in disarray after moving out. The article states that the former home of Myriad Genetics at 468 Littlefield Ave. in South San Francisco is now vacant. Further details about the specific allegations are not provided in this preview.
Is FDA and Reimbursement Momentum Altering The Investment Case For Guardant Health (GH)?
Guardant Health (GH) recently reported strong quarterly revenue, exceeding analyst expectations, driven by progress in FDA submissions, reimbursement expansion, and margin improvement. While the company faces ongoing concerns about profitability and cash burn, these developments suggest positive operational momentum. The investment narrative hinges on liquid biopsy becoming a large cancer testing franchise, with regulatory and payer traction being key catalysts for future growth and reduced equity financing risk.
Beware the Vortex! How a $197 hair gadget sparked a three-month fight with American Express
Joanne Pantaleo bought a $197 Vortex Hair Growth Wand advertised by a U.S.-based company, but when it failed, she discovered the return address was a Chinese warehouse with a $120 shipping fee. American Express initially sided with the merchant on her dispute, despite evidence of misrepresentation. After consumer advocate Christopher Elliott intervened, Amex offered Pantaleo a $100 good-faith credit, highlighting the challenges consumers face with companies that make returns prohibitively expensive.
First National Bank of Omaha Invests $8.83 Million in Quest Diagnostics Incorporated $DGX
First National Bank of Omaha has acquired a new position of 46,332 shares in Quest Diagnostics (NYSE:DGX) valued at approximately $8.83 million. This investment comes despite recent insider selling by the CEO and other directors totaling over $22 million. Quest Diagnostics reported strong quarterly earnings, exceeded revenue expectations, authorized a $1 billion share buyback, and increased its quarterly dividend.
Advisors Capital Management LLC Acquires 14,258 Shares of Quest Diagnostics Incorporated $DGX
Advisors Capital Management LLC increased its stake in Quest Diagnostics (NYSE:DGX) by 5% in Q3, purchasing 14,258 additional shares and bringing its total holdings to 297,644 shares valued at approximately $56.7 million. Quest Diagnostics recently reported strong quarterly results, beating EPS and revenue estimates, and announced a dividend increase to $0.86 as well as a $1.00 billion share buyback program. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $210.29, reflecting positive sentiment.
Piper Sandler Adjusts Price Target on Quest Diagnostics to $215 From $200, Maintains Neutral Rating
Piper Sandler has increased its price target for Quest Diagnostics (DGX) to $215 from $200, while maintaining a Neutral rating on the stock. This adjustment reflects a moderated outlook for the company's valuation by the firm. The article also provides a brief overview of recent insider transactions and other analyst ratings for Quest Diagnostics.
Skandinaviska Enskilda Banken AB publ Sells 27,243 Shares of Quest Diagnostics Incorporated $DGX
Skandinaviska Enskilda Banken AB publ has reduced its stake in Quest Diagnostics (NYSE:DGX) by selling 27,243 shares, now holding 161,916 shares valued at approximately $30.86 million. This move comes as Quest Diagnostics reported a Q3 EPS beat of $2.42 per share, with revenue up 7.1% year-over-year, and announced a $1 billion share buyback program and an increased quarterly dividend to $0.86. Despite this sale, other institutional investors have recently increased their positions in the medical research company.
DNA RNA Banking Services Market Is Going to Boom | Thermo Fisher Scientific • Illumina • 23andMe • AncestryDNA
This report by Coherent Market Insights analyzes the DNA RNA Banking Services Market, predicting substantial growth from 2026 to 2033 due to rising demand and innovation. It covers key market trends, drivers, competitive landscape, and strategic opportunities for industry leaders, identifying major players like Thermo Fisher Scientific and Illumina. The study utilizes analytical tools like SWOT analysis and Porter's Five Forces to provide comprehensive insights and forecasts for various segments and regions.
Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow
Guardant Health (GH) is set to report its Q4 results tomorrow after market hours, with analysts expecting a 34.6% year-on-year revenue growth to $271.7 million and an adjusted loss of -$0.47 per share. The company has consistently beaten revenue estimates in the past two years. Despite general underperformance in the testing & diagnostics services segment, Guardant Health has an average analyst price target of $125 against its current share price of $107.54.
Labcorp forecasts upbeat annual profit on strong demand for diagnostic products
Labcorp (LH.N) has projected an upbeat annual profit, surpassing Wall Street estimates, driven by strong demand for its diagnostic tests and services. The company expects its diagnostic segment to grow between 5% and 6% in 2026, anticipating an annual adjusted profit per share of $17.55 to $18.25. This positive outlook is supported by steady demand for non-urgent surgeries and successful agreements to manage hospital laboratories.
5 Insightful Analyst Questions From Quest's Q4 Earnings Call
Quest Diagnostics (DGX) exceeded revenue and earnings expectations in Q4, driven by strong organic growth and new partnerships. The article highlights key analyst questions from the earnings call, focusing on core growth drivers in 2026, margin impacts from new collaborations, competitive positioning, oncology test reimbursement, and the sustainability of consumer testing. Management provided insights into these areas, emphasizing growth in specialized testing and operational improvements.
Cibc World Market Inc. Increases Stake in Quest Diagnostics Incorporated $DGX
Cibc World Market Inc. significantly increased its stake in Quest Diagnostics (NYSE:DGX) by 209.6% in Q3, now holding 7,765 shares valued at $1.48 million. Quest Diagnostics also reported strong quarterly earnings, beating estimates with $2.42 EPS and $2.81 billion in revenue, and announced a $1 billion share buyback program and a dividend increase. Analysts have a "Moderate Buy" rating on the stock with a consensus price target of $208.93.
Brookdale (BKD) Reports Q4: Everything You Need To Know Ahead Of Earnings
Brookdale Senior Living (BKD) is set to announce its Q4 earnings results after market close this Wednesday. Analysts anticipate a 1.8% year-on-year revenue decline to $767 million and an adjusted loss of -$0.18 per share. Despite an average analyst price target of $19, the company missed revenue and EPS expectations in the previous quarter.
M&G PLC Has $208.26 Million Stake in Quest Diagnostics Incorporated $DGX
M&G PLC increased its stake in Quest Diagnostics (NYSE:DGX) by 1.6% to 1,090,377 shares, valued at $208.26 million, highlighting significant institutional interest with 88.06% ownership across various firms. Quest Diagnostics recently reported strong Q4 results, surpassing earnings and revenue expectations, and announced a $1.0 billion share buyback program and a dividend increase to $0.86, reflecting financial health and management confidence. Despite insider selling, analysts maintain a "Moderate Buy" consensus, with several upgrading price targets, suggesting continued positive outlook for the company which is currently trading near its 52-week high.
3 Reasons to Avoid NVST and 1 Stock to Buy Instead
This article advises investors to avoid Envista Holdings Corp (NVST) despite its recent stock performance. The author highlights three main reasons: disappointing long-term revenue growth, previous growth initiatives losing money due to negative ROIC, and a decline in new investment returns. Instead, the article suggests looking into the most entrenched endpoint security platform on the market and provides a link to "Top 6 Stocks" list.
Labcorp (LH) To Report Earnings Tomorrow: Here Is What To Expect
Labcorp (LH) is set to announce its earnings results on Tuesday before market hours. Analysts anticipate a 7.2% year-on-year revenue growth to $3.57 billion and adjusted earnings of $3.94 per share. The company has generally met or exceeded revenue estimates in the past, and its stock has recently outperformed its peers in the healthcare providers & services segment.
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For
NeoGenomics (NEO) is set to release its Q4 earnings report this Tuesday. Analysts anticipate a 9.5% year-on-year revenue growth to $188.3 million and adjusted earnings of $0.04 per share. The company has a history of missing Wall Street revenue estimates, and its stock has underperformed peers in the healthcare providers & services segment recently.
Labcorp (LH) To Report Earnings Tomorrow: Here Is What To Expect
Labcorp (LH) is set to report its earnings tomorrow before market hours. Analysts expect the company's revenue to grow 7.2% year-on-year to $3.57 billion, with adjusted earnings anticipated at $3.94 per share. While the healthcare providers & services segment has generally underperformed, Labcorp's shares are up 4.2% over the last month and it heads into earnings with an average analyst price target higher than its current share price.
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For
NeoGenomics (NEO) is set to announce its Q4 earnings results. Analysts expect revenue growth of 9.5% year-on-year to $188.3 million and adjusted earnings of $0.04 per share. The company has a history of missing Wall Street's revenue estimates and its shares have underperformed the healthcare sector recently.
Quest Diagnostics (DGX) Is Up 8.5% After Strong 2026 Guidance And New Myeloma Test Launch - Has The Bull Case Changed?
Quest Diagnostics (DGX) recently reported strong Q4 and full-year 2025 results, issued optimistic 2026 guidance, raised its dividend, and expanded its share repurchase authorization. The company also launched an innovative blood-based multiple myeloma test, combining advanced oncology solutions with a larger buyback. This article examines how these developments, including projected revenues and earnings, reshape Quest Diagnostics' investment outlook amidst continued reliance on its lab network and advanced diagnostics, along with potential reimbursement risks.
Rhumbline Advisers Decreases Stock Holdings in Quest Diagnostics Incorporated $DGX
Rhumbline Advisers reduced its stake in Quest Diagnostics by 1.9% in Q3, now holding 274,446 shares valued at $52.3 million. Despite this, other institutional investors increased their holdings. Quest Diagnostics surpassed Q4 earnings and revenue estimates, announced a $1.0 billion share repurchase, and increased its quarterly dividend to $0.86 per share, signaling positive corporate actions.
HIVE’s CA$30 Million AI Contracts Test Shift Beyond Crypto Mining
HIVE Digital Technologies has secured approximately CA$30 million in long-term AI cloud customer contracts through its BUZZ high-performance computing division. These multi-year agreements will support a large GPU cluster deployment at HIVE's Manitoba facility, marking a strategic shift towards AI infrastructure alongside its traditional crypto mining operations. This move comes as HIVE's share price has faced recent pressure, providing a concrete development for investors to monitor its expansion into new areas.
ING Groep NV Makes New Investment in Quest Diagnostics Incorporated $DGX
ING Groep NV has acquired a new stake in Quest Diagnostics Incorporated, purchasing 16,648 shares valued at approximately $3.17 million. This investment comes as Quest Diagnostics shows positive momentum, including strong Q4 results, a new share repurchase authorization, and an increased dividend. Several other institutional investors also adjusted their holdings, with the stock currently rated a "Moderate Buy" by analysts.
Quest Diagnostics: Q4 Earnings Snapshot
Quest Diagnostics (DGX) reported strong fourth-quarter results, surpassing Wall Street expectations for both profit and revenue. The medical laboratory operator posted $2.18 profit per share, or $2.42 adjusted, on revenue of $2.81 billion. For the full year, the company had $8.75 earnings per share and $11.04 billion in revenue and provided an optimistic outlook for the upcoming fiscal year.
OPCH Stock Price, Forecast & Analysis | OPTION CARE HEALTH INC (NASDAQ:OPCH)
This article provides an analysis of OPTION CARE HEALTH INC (OPCH) stock, detailing its current price, technical and fundamental ratings, and market performance. It includes key statistics, financial highlights, analyst forecasts predicting a 14.67% price increase, and information about its competitors and company profile.
Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.86
Quest Diagnostics (NYSE:DGX) has announced an increase in its quarterly dividend to $0.86, resulting in a 1.7% dividend yield. The dividend is comfortably covered by the company's cash flow and earnings, with EPS forecast to expand by 30.1% next year. While the company has a solid track record of increasing dividends, the past five years have seen an approximate 3.3% annual decline in earnings per share, raising some caution despite positive forecasts for the upcoming year.
Quest Diagnostics Incorporated $DGX Shares Sold by Cookson Peirce & Co. Inc.
Cookson Peirce & Co. Inc. reduced its stake in Quest Diagnostics by 3.6%, selling 6,032 shares. Despite this, Quest Diagnostics reported strong Q4 results, surpassing analyst expectations for both EPS and revenue, and announced a $1.0 billion stock repurchase plan and an increased quarterly dividend. Insider selling activities were noted, with CEO J.E. Davis selling a significant number of shares.
Quest Diagnostics MRD Blood Test May Support Growth In Higher Value Oncology
Quest Diagnostics (NYSE:DGX) has launched a new blood-based minimal residual disease (MRD) test for multiple myeloma, which offers comparable sensitivity to next-generation sequencing at a lower cost and is less invasive. This development expands Quest’s oncology specialty test menu, aligning with FDA guidance recognizing MRD as a clinical trial endpoint. Investors should monitor how this higher-value diagnostic contributes to oncology revenue, test volumes, payer coverage, and its role in clinical trials, while also considering Quest's debt levels.
Quest Diagnostics (NYSE:DGX) SVP Sells 5,662 Shares
Quest Diagnostics (NYSE:DGX) SVP Patrick Plewman sold 5,662 shares of the company's stock for over $1.15 million on February 10th, reducing his ownership by 26.91%. This comes after Quest Diagnostics reported better-than-expected Q4 earnings and revenue, raised its dividend, and authorized a $1 billion share buyback program. Analysts have largely maintained "Buy" or "Hold" ratings with an average target price of $208.93.
Mizuho Issues Positive Forecast for Quest Diagnostics (NYSE:DGX) Stock Price
Mizuho has raised its price target for Quest Diagnostics (NYSE:DGX) to $235 from $210, maintaining an "outperform" rating and implying a 12.3% upside. This follows Quest Diagnostics beating quarterly earnings expectations with $2.42 EPS and $2.81 billion in revenue, and announcing a $1.00 billion share buyback program. Other analysts have also adjusted their price targets, with the stock currently holding a "Moderate Buy" consensus rating.
Personalis Data Breach Lawsuit Investigation
Shamis & Gentile P.A. is investigating a data breach at Personalis, Inc., a biotechnology company. The breach, reported on February 4, 2026, affected approximately 650 people in the US, potentially exposing sensitive personally identifiable information (PII) and protected health information (PHI). Individuals whose data was compromised may be entitled to compensation and are encouraged to join the ongoing lawsuit.
Quest Diagnostics MRD Blood Test May Support Growth In Higher Value Oncology
Quest Diagnostics has launched a new blood-based minimal residual disease (MRD) test for multiple myeloma, which offers sensitivity comparable to next-generation sequencing but with lower cost and less invasive sampling. This development expands Quest’s oncology testing capabilities into a higher-value segment. The commercial success of the test will depend on factors like payer coverage, clinical adoption, and its role in future multiple myeloma therapies and trials.
Quest Diagnostics (DGX): Analyst Raises Price Target to $235 | D
Mizuho analyst Ann Hynes maintained an "Outperform" rating on Quest Diagnostics (DGX) and increased the price target from $210.00 to $235.00, representing an 11.90% jump. This positive adjustment aligns with several other analysts who have also raised their price targets for the company. Quest Diagnostics, a leading diagnostic testing provider, shows a collective favorable sentiment from market watchers, even though GuruFocus's estimated GF Value suggests a potential downside from its current price.
Rothschild & Co Redburn Adjusts Quest Diagnostics PT to $224 From $200, Maintains Buy Rating
Rothschild & Co Redburn has increased its price target for Quest Diagnostics (DGX) to $224, up from the previous $200, while reiterating a "Buy" rating on the stock. This adjustment reflects a positive outlook for the company. The article also lists several other analysts who have adjusted their price targets for Quest Diagnostics around the same time, mostly upwards, indicating broad analyst confidence.
Thrivent Financial for Lutherans Decreases Holdings in Quest Diagnostics Incorporated $DGX
Thrivent Financial for Lutherans reduced its stake in Quest Diagnostics Incorporated (DGX) by 58.3% in the third quarter of 2025, selling 14,080 shares and holding 10,087 shares valued at $1.922 million. This move comes as company insiders, including CEO J. E. Davis, have also been net sellers of the stock. Despite insider selling and a 2026 EPS guidance that fell below some estimates, Quest Diagnostics reported strong Q4 results, a $1.0 billion share buyback, and a 7.5% dividend increase.
Forecasting The Future: 6 Analyst Projections For Quest Diagnostics
Six analysts have issued ratings for Quest Diagnostics (NYSE: DGX) over the last three months, with an average price target of $218.33, marking a 9.17% increase. The company's financials show a strong market capitalization and an impressive net margin of 8.63%, despite a slower revenue growth rate compared to some peers in the Health Care sector. Analysts have consistently raised their price targets for DGX, reflecting positive sentiment.
Deutsche Bank Adjusts Quest Diagnostics Price Target to $205 From $178, Maintains Hold Rating
Deutsche Bank has increased its price target for Quest Diagnostics (DGX) to $205 from $178, while maintaining a Hold rating on the stock. This adjustment comes amidst several other analyst firms also updating their price targets and ratings for Quest Diagnostics, following the company's recent strong Q4 2025 earnings and positive 2026 guidance. Quest Diagnostics also announced an increase in its quarterly cash dividend and a $1 billion increase in its share repurchase authorization.
DGX: Evercore ISI Group Raises Price Target for Quest Diagnostics | DGX Stock News
Evercore ISI Group has raised its price target for Quest Diagnostics (DGX) to $220 from $190, while maintaining an "In-Line" rating. This adjustment reflects a 15.79% increase and comes amidst similar positive adjustments from other analytical firms, indicating strong confidence in the company's growth prospects. Despite the optimistic analyst forecasts, GuruFocus estimates a potential downside based on its GF Value fair value calculation.
Is Grainger Stock Overvalued in 2026 After a 15% Rally Last Year?
W.W. Grainger (GWW) guided 2026 sales to $19 billion with a 15-16% operating margin. Despite a 15% rally in 2025 and J.P.Morgan raising its price target, TIKR's valuation model suggests GWW stock is overvalued with an annualized return of 7.5% over 2.9 years, falling short of a typical 10% equity hurdle rate, prompting a "Sell" signal. Key assumptions for the model include 6.4% revenue growth, 15.8% operating margins, and a 25.3x exit P/E multiple.
DGX: Jefferies Raises Target Price for Quest Diagnostics to $220
Jefferies has reiterated its "Buy" rating for Quest Diagnostics (DGX) and increased its price target from $215 to $220. This adjustment reflects positive expectations for the company's future performance. Other analysts have also recently updated their ratings and price targets, indicating a general sentiment of growth for Quest Diagnostics, a leading independent provider of diagnostic testing services in the US.
Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI Efficiency
Quest Diagnostics (DGX) is transforming its business by aggressively pivoting towards advanced diagnostics and AI-driven efficiency, leading to a fresh 52-week high for its shares. This shift, combined with a strong fourth-quarter earnings report and a legislative reprieve on Medicare reimbursement rates, positions Quest as a critical "lab engine" in the evolving healthcare landscape, particularly in precision medicine. The company is focusing on innovations like AD-Detect for Alzheimer's and Haystack MRD for cancer monitoring, while also streamlining operations through "Project Nova" and navigating competitive and regulatory challenges.
Quest Diagnostics Shares Jump on Q4 Beat; FY25 Revenue Rises, 2026 Outlook Raised
Quest Diagnostics (NYSE: DGX) shares surged by 6.56% following a strong Q4 and full-year 2025 earnings report. The company reported significant revenue and EPS growth in 2025, driven by diagnostic testing demand and strategic initiatives. Quest Diagnostics also provided an optimistic 2026 guidance, forecasting continued top- and bottom-line expansion.
Quest Diagnostics hits 52-week high as outlook tops consensus
Quest Diagnostics reached a new 52-week high after releasing an optimistic financial outlook that surpassed analyst expectations. This positive forecast likely contributed to the rise in stock value, indicating strong investor confidence in the company's future performance.
Quest Diagnostics Inc. stock outperforms competitors on strong trading day
Quest Diagnostics Inc. (DGX) stock saw a positive performance, rising 0.65% to $139.75, which outpaced its competitors on a generally strong trading day. While the S&P 500 also increased, Quest Diagnostics notably outperformed several key rivals in the medical laboratory and research industry. This positive movement comes amidst recent dips in the company's stock value, as observed over the past few weeks and months.
Quest Diagnostics Signals Growth Amid Margin Pressures
Quest Diagnostics (DGX) reported strong Q4 2025 earnings, with broad-based organic revenue growth, increased test volumes, and double-digit full-year revenue and EPS growth. Despite this strong performance, the company faces near-term margin pressures due to new low-margin partnerships, modest pricing pressure, and regulatory uncertainties like PAMA. Quest is investing in advanced diagnostics, consumer channels, and AI-driven productivity initiatives to mitigate these headwinds and drive future growth.
Jefferies Maintains Buy on Quest Diagnostics (DGX) Feb 10, 2026
Jefferies maintained its Buy rating on Quest Diagnostics (DGX) on February 10, 2026, while raising its price target from $215 to $220. This decision was driven by Quest Diagnostics' stronger-than-expected Q4 results and optimistic 2026 guidance, signaling confidence in the company's operational momentum. Meyka AI also rates DGX with a B+ grade, reflecting positive sentiment based on various financial metrics and analyst consensus, although the stock has experienced recent mixed price movements.
